|
| Status |
Public on Apr 11, 2019 |
| Title |
7584066_6_Post whole blood draw, T6, Post-injection |
| Sample type |
RNA |
| |
|
| Source name |
Whole blood
|
| Organism |
Homo sapiens |
| Characteristics |
time point: T6
response: Poor
ms type: CIS
age: 32.13689254
gender: F
race: White
|
| Treatment protocol |
Subjects were injected with intramuscular IFN-β1a (Avonex®) precisely 12 hours before blood was drawn.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA extractions were completed on Arrayplex (Beckman Coulter, Indianapolis, IN) using Agencourt RNAdvance Blood kit (Part number A35604) according to the manufacturer’s specifications.
|
| Label |
biotin
|
| Label protocol |
Automated sample amplifications and biotin labelings were carried out using the NuGEN Ovation RNA Amplification system V2 (Cat # 3100), Ovation WB reagent (Cat # 1300) and Encore Biotin module (Cat # 4200) (NuGEN Technologies, Inc, San Carlos, CA) according to manufacturer’s recommendations using an Arrayplex automated liquid handler (Beckman Coulter, Indianapolis, IN).
|
| |
|
| Hybridization protocol |
2 ug of biotin labeled sscDNA probe were hybridized to Affymetrix GeneChip HT HG-U133+ PM plate arrays with modified conditions as described in Allaire et al[PMID:23289891].
|
| Scan protocol |
The processed GeneChip plate arrays were scanned using GeneTitan scanner (Affymetrix, Santa Clara, CA).
|
| Data processing |
The data were analyzed with the R Bioconductor affy package using RMA normalization.
|
| |
|
| Submission date |
Apr 11, 2018 |
| Last update date |
Apr 11, 2019 |
| Contact name |
Mark R Chance |
| Organization name |
Case Western Reserve University School of Medicine
|
| Street address |
10900 Euclid Ave
|
| City |
Cleveland |
| State/province |
OH |
| ZIP/Postal code |
44106 |
| Country |
USA |
| |
|
| Platform ID |
GPL13158 |
| Series (2) |
| GSE113006 |
Expression data from whole blood of RRMS patients initiating treatment with intramuscular IFN-β1a (Avonex®) obtained exactly 12 hours after treatment. |
| GSE113007 |
Expression data from whole blood of RRMS patients initiating treatment with intramuscular IFN-β1a (Avonex®) |
|
